Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Lisa C. Holthof; Hilma J. van der Horst; Susan E. van Hal-van Veen; Ruud W.J. Ruiter; Fengzhi Li; Marijke Buijze; Morten N. Andersen; Huipin Yuan; Joost de Bruijn; Niels W.C.J. van de Donk; Henk M. Lokhorst; Sonja Zweegman; Richard W.J. Groen; Tuna Mutis

doi:https://doi.org/10.3324/haematol.2018.213314

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Lisa C. Holthof, Hilma J. van der Horst, Susan E. van Hal-van Veen, Ruud W.J. Ruiter, Fengzhi Li, Marijke Buijze, Morten N. Andersen, Huipin Yuan, Joost de Bruijn, Niels W.C.J. van de Donk, Henk M. Lokhorst, Sonja Zweegman, Richard W.J. Groen, Tuna Mutis

Research output: Contribution to journal › Letter › Academic › peer-review

11 Citations (Scopus)

Original language	English
Pages (from-to)	e80-e83
Journal	Haematologica
Volume	105
Issue number	2
Early online date	23 May 2019
DOIs	https://doi.org/10.3324/haematol.2018.213314
Publication status	Published - 31 Jan 2020

Access to Document

https://doi.org/10.3324/haematol.2018.213314

Cite this

Holthof, L. C., van der Horst, H. J., van Hal-van Veen, S. E., Ruiter, R. W. J., Li, F., Buijze, M., Andersen, M. N., Yuan, H., de Bruijn, J., van de Donk, N. W. C. J., Lokhorst, H. M., Zweegman, S., Groen, R. W. J., & Mutis, T. (2020). Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. Haematologica, 105(2), e80-e83. https://doi.org/10.3324/haematol.2018.213314

@article{0998833f00884bcc81e0c5ecc9dad87d,

title = "Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma",

author = "Holthof, {Lisa C.} and {van der Horst}, {Hilma J.} and {van Hal-van Veen}, {Susan E.} and Ruiter, {Ruud W.J.} and Fengzhi Li and Marijke Buijze and Andersen, {Morten N.} and Huipin Yuan and {de Bruijn}, Joost and {van de Donk}, {Niels W.C.J.} and Lokhorst, {Henk M.} and Sonja Zweegman and Groen, {Richard W.J.} and Tuna Mutis",

note = "Copyright {\textcopyright} 2019, Ferrata Storti Foundation.",

year = "2020",

month = jan,

day = "31",

doi = "https://doi.org/10.3324/haematol.2018.213314",

language = "English",

volume = "105",

pages = "e80--e83",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "2",

}

Holthof, LC, van der Horst, HJ, van Hal-van Veen, SE, Ruiter, RWJ, Li, F, Buijze, M, Andersen, MN, Yuan, H, de Bruijn, J, van de Donk, NWCJ, Lokhorst, HM, Zweegman, S , Groen, RWJ & Mutis, T 2020, 'Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma', Haematologica, vol. 105, no. 2, pp. e80-e83. https://doi.org/10.3324/haematol.2018.213314

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. / Holthof, Lisa C.; van der Horst, Hilma J.; van Hal-van Veen, Susan E. et al.
In: Haematologica, Vol. 105, No. 2, 31.01.2020, p. e80-e83.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

AU - Holthof, Lisa C.

AU - van der Horst, Hilma J.

AU - van Hal-van Veen, Susan E.

AU - Ruiter, Ruud W.J.

AU - Li, Fengzhi

AU - Buijze, Marijke

AU - Andersen, Morten N.

AU - Yuan, Huipin

AU - de Bruijn, Joost

AU - van de Donk, Niels W.C.J.

AU - Lokhorst, Henk M.

AU - Zweegman, Sonja

AU - Groen, Richard W.J.

AU - Mutis, Tuna

PY - 2020/1/31

Y1 - 2020/1/31

UR - http://www.scopus.com/inward/record.url?scp=85078815701&partnerID=8YFLogxK

U2 - https://doi.org/10.3324/haematol.2018.213314

DO - https://doi.org/10.3324/haematol.2018.213314

M3 - Letter

C2 - 31123033

SN - 0390-6078

VL - 105

SP - e80-e83

JO - Haematologica

JF - Haematologica

IS - 2

ER -

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Access to Document

Other files and links

Cite this